Abstract:Background A phase 2 study was done to evaluate the safety and efficacy of clofarabine in paediatric patients with refractory or relapsed acute lymphoblastic leukaemia (ALL) in China. Methods Patients aged 1–21 years with histologically confirmed, relapsed or refractory ALL were eligible. Clofarabine was administered intravenously for 5 days at 52 mg/m2 per day during induction and consolidation. The primary endpoint was overall remission rate (ORR; complete remission [CR] plus CR with incomplete counts [CRi]). Blood samples were collected for pharmacokinetic analysis. Findings A total of 44 patients were enrolled, of whom 43 were evaluable for response. The median age was 13 years (range 5–22 years), and the majority were B cell-ALL (75%, 33/44). The ORR was 44.2% (19/43), including two CR and 17 CRi. 39 patients had progressive disease at cut-off time; the overall median remission duration was 2.9 months, and 3.4 months for patients achieved CR or CRi. Subgroup analysis showed that efficacy differed significantly by age and phenotype of the cell (age <14 years versus age ⩾14 years: 60.9% versus 25%, p = 0.0308; B-cell ALL versus T-cell ALL: 57.6% versus 0, p = 0.002). The most common (⩾10%) adverse reactions (ADRs) were haematological toxicity, gastrointestinal reaction, and abnormal liver function, and the most common grade 3 or 4 non-haematological ADR was ALT elevation (13.6%). PK analysis showed that after multiple administrations the mean elimination half-life of clofarabine was 6.43 h, and the Tmax was around 2 h. The mean Cmax and exposure to clofarabine over the dosing period (AUC 0–24) were 581 μg/L and 2602.56 μg/L, respectively. Interpretation Single-agent clofarabine treatment is effective in Chinese paediatric patients with multiple relapsed or refractory ALL, with an acceptable safety profile. A phase 2 study was done to evaluate the safety and efficacy of clofarabine in paediatric patients with refractory or relapsed acute lymphoblastic leukaemia (ALL) in China. Patients aged 1–21 years with histologically confirmed, relapsed or refractory ALL were eligible. Clofarabine was administered intravenously for 5 days at 52 mg/m2 per day during induction and consolidation. The primary endpoint was overall remission rate (ORR; complete remission [CR] plus CR with incomplete counts [CRi]). Blood samples were collected for pharmacokinetic analysis. A total of 44 patients were enrolled, of whom 43 were evaluable for response. The median age was 13 years (range 5–22 years), and the majority were B cell-ALL (75%, 33/44). The ORR was 44.2% (19/43), including two CR and 17 CRi. 39 patients had progressive disease at cut-off time; the overall median remission duration was 2.9 months, and 3.4 months for patients achieved CR or CRi. Subgroup analysis showed that efficacy differed significantly by age and phenotype of the cell (age <14 years versus age ⩾14 years: 60.9% versus 25%, p = 0.0308; B-cell ALL versus T-cell ALL: 57.6% versus 0, p = 0.002). The most common (⩾10%) adverse reactions (ADRs) were haematological toxicity, gastrointestinal reaction, and abnormal liver function, and the most common grade 3 or 4 non-haematological ADR was ALT elevation (13.6%). PK analysis showed that after multiple administrations the mean elimination half-life of clofarabine was 6.43 h, and the Tmax was around 2 h. The mean Cmax and exposure to clofarabine over the dosing period (AUC 0–24) were 581 μg/L and 2602.56 μg/L, respectively. Single-agent clofarabine treatment is effective in Chinese paediatric patients with multiple relapsed or refractory ALL, with an acceptable safety profile.

Clofarabine Acts as Radiosensitizer In Vitro and In Vivo by Interfering With DNA Damage Response

In Vivo Cytotoxic, Genotoxic and Radiosensitizing Effects of Clofarabine

Clofarabine Has a Superior Therapeutic Window as compared to Gemcitabine in Preclinical Bladder Cancer Models

Inhibition of breast cancer cell growth by the combination of clofarabine and sulforaphane involves epigenetically mediated CDKN2A upregulation

[RAD001 Reverses Radio-Resistance and Exerts Synergistic Tumor Inhibition with 5-Fluorouracil].

Single Arm, Multi-Center, Phase Ii Study Of Clofarabine In Chinese Pediatric Patients With Refractory Or Relapsed Acute Lymphoblastic Leukemia

Abstract 557: Clofarabine inhibits U87MG glioblastoma cell line proliferation through CD99 signaling pathway

[Therapeutic Effect of Clofarabine in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia].

Optimal piecewise-constant signal design for active fault detection

Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell Transplantation

Cellular and Clinical Pharmacology of Fludarabine

FK228 sensitizes radioresistant small cell lung cancer cells to radiation

Fludarabine Enhances Radiosensitivity by Promoting Ferroptosis in B-Cell Lymphoma

OP0003 Single arm, multicentre, phase 2 study of clofarabine in Chinese paediatric patients with refractory or relapsed acute lymphoblastic leukaemia

Decitabine Sensitizes The Radioresistant Lung Adenocarcinoma To Pemetrexed Through Upregulation Of Folate Receptor Alpha

Quantification of clofarabine in urine and plasma by LC-MS/MS: suitable for PK study and TDM in pediatric patients with relapsed or refractory ALL

FACT inhibitor CBL0137, administered in an optimized schedule, potentiates radiation therapy for glioblastoma by suppressing DNA damage repair

Clofarabine Preconditioning followed by Allogeneic Transplant Using TBI and Post-Transplant Cyclophosphamide for Relapsed Refractory Leukemia

Antiandrogen Therapy Radiosensitizes Androgen Receptor-Positive Cancers to 18F-FDG

Leukemia: A model for drug development

Enhancing Antitumor Efficacy of Nucleoside Analog 5-Fluorodeoxyuridine on HER2-Overexpressing Breast Cancer by Affibody-Engineered DNA Nanoparticle